Literature DB >> 8558014

IL-12, as an adjuvant, promotes a T helper 1 cell, but does not suppress a T helper 2 cell recall response.

J Bliss1, V Van Cleave, K Murray, A Wiencis, M Ketchum, R Maylor, T Haire, C Resmini, A K Abbas, S F Wolf.   

Abstract

IL-12 is a potent inducer of NK and cytolytic T cell activity, IFN-gamma production, and T cell proliferation, and is necessary for differentiation of naive T cells to the Th1 subset. We have previously shown that IL-12 promotes a primary Th1 response and suppresses a primary Th2 response in lymph nodes of mice primed with a model hapten-protein conjugate, 2,4,6-trinitrophenyl (TNP)-keyhole limpet hemocyanin (KLH). We have now extended these studies to determine the Th phenotype of the recall response following immunization with soluble Ag and IL-12. For these experiments, mice were primed with TNP-KLH with or without treatment with IL-12, allowed to progress beyond the primary immune response, and challenged by i.p. injection of TNP-KLH. The phenotype of the recall response was monitored by measuring ex vivo production of IFN-gamma and IL-4 in Ag-stimulated lymph node and spleen cell cultures. Titer and isotype of TNP-specific serum Abs were also evaluated. Mice primed with Ag+IL-12 developed a Th1 recall response, as detected by KLH-specific IFN-gamma production from cultured spleen cells and the presence of TNP-specific IgG2a Ab in serum. However, they also developed an Ag-specific Th2 recall response, as characterized by Ag-induced IL-4 production from spleen cells and the presence of high titers of anti-TNP IgG1 in the serum. Studies of the cytokine profile during the primary response revealed that IL-12 induced in spleen cells the capacity to express both IL-4 and IFN-gamma. CD4+ T cells are necessary for production of IL-4 in the spleens of IL-12-treated mice, and most likely account for the Th2 recall response detected in mice primed with Ag+IL-12. These results indicate that the Th1 phenotype induced by immunization with IL-12 and Ag is maintained so that a Th1 recall response is expressed upon subsequent challenge with Ag. However, immunization with IL-12 also supports the development of a Th2 recall response, indicating that the Th1-inducing effect of IL-12 in vivo is not accompanied by a long lasting suppression of Th2 development.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8558014

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  28 in total

1.  Dose-dependent and schedule-dependent effects of interleukin-12 on antigen-specific CD8 responses.

Authors:  K Lee; W W Overwijk; M O'Toole; H Swiniarski; N P Restifo; A J Dorner; S F Wolf; K Sturmhoefel
Journal:  J Interferon Cytokine Res       Date:  2000-06       Impact factor: 2.607

2.  Interleukin-12 as an adjuvant for an antischistosome vaccine consisting of adult worm antigens: protection of rats from cercarial challenge.

Authors:  R D Bungiro; M Goldberg; P K Suri; P M Knopf
Journal:  Infect Immun       Date:  1999-05       Impact factor: 3.441

3.  Interleukin-12 is capable of generating an antigen-specific Th1-type response in the presence of an ongoing infection-driven Th2-type response.

Authors:  L R Schopf; J L Bliss; L M Lavigne; C L Chung; S F Wolf; J P Sypek
Journal:  Infect Immun       Date:  1999-05       Impact factor: 3.441

4.  Experimental hypersensitivity pneumonitis: influence of Th2 bias.

Authors:  M Schuyler; K Gott; V Mapel; A Cherne; K J Nikula
Journal:  Int J Exp Pathol       Date:  1999-12       Impact factor: 1.925

5.  Interleukin-12 promotes activation of effector cells that induce a severe destructive granulomatous form of murine experimental autoimmune thyroiditis.

Authors:  H Braley-Mullen; G C Sharp; H Tang; K Chen; M Kyriakos; J T Bickel
Journal:  Am J Pathol       Date:  1998-05       Impact factor: 4.307

6.  Acute and chronic phases of Toxoplasma gondii infection in mice modulate the host immune responses.

Authors:  T D Nguyen; G Bigaignon; J Van Broeck; M Vercammen; T N Nguyen; M Delmee; M Turneer; S F Wolf; J P Coutelier
Journal:  Infect Immun       Date:  1998-06       Impact factor: 3.441

7.  Intranasal vaccination with pneumococcal surface protein A and interleukin-12 augments antibody-mediated opsonization and protective immunity against Streptococcus pneumoniae infection.

Authors:  B P Arulanandam; J M Lynch; D E Briles; S Hollingshead; D W Metzger
Journal:  Infect Immun       Date:  2001-11       Impact factor: 3.441

8.  Inability of interleukin-12 to modulate T-helper 0 effectors to T-helper 1 effectors: a possible distinct subset of T cells.

Authors:  C Hu; P Salgame
Journal:  Immunology       Date:  1999-05       Impact factor: 7.397

9.  Administration of interleukin-12 exerts a therapeutic instead of a long-term preventive effect on mite Der p I allergen-induced animal model of airway inflammation.

Authors:  Y Lee; C Fu; B Chiang
Journal:  Immunology       Date:  1999-06       Impact factor: 7.397

10.  Genetic immunization elicits antigen-specific protective immune responses and decreases disease severity in Trypanosoma cruzi infection.

Authors:  Nisha Garg; Rick L Tarleton
Journal:  Infect Immun       Date:  2002-10       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.